Cognition

Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, March 21, 2024
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Modafinil, Research, Depression, EEG, DSM-IV codes, Histamine, Brain, Regenerative medicine, CFO, NMDA, MDD, Partnership, Patient, CNS, CIAS, Neuroscience, CIRM, Anhedonia, IPO, PDE4, Overalls, IND, Biogen, Cognition, Johnson & Johnson, Central nervous system disease, Pharmaceutical industry

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today reported financial results for the full year ended December 31, 2023, and highlighted recent corporate progress.

Key Points: 
  • Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today reported financial results for the full year ended December 31, 2023, and highlighted recent corporate progress.
  • In January 2023, Alto reported positive results from a Phase 2a study in which patients with MDD and a cognitive biomarker signature were identified as more responsive to ALTO-100.
  • Alto is currently evaluating ALTO-100 in a 266-patient Phase 2b study in MDD patients characterized by the cognitive biomarker.
  • The increase was primarily attributable to costs associated with the Phase 2a clinical studies for ALTO-100 and ALTO-300, which were completed in 2023.

Thiel Foundation Announces Next Thiel Fellow Class

Retrieved on: 
Thursday, March 21, 2024
Robotics, Engineering, Environment, Technology, Aerospace, Cryptocurrency, Manufacturing, Semiconductor, Security, Photography, Health Technology, Fintech, Foundation, Artificial Intelligence, Banking, University, Professional Services, Education, Philanthropy, Health, Software, Hardware, Ethereum, Loom, Farmer, Devin, OpenAI, Hyperplane, Paralysis, Reformation, Oligo, History, AI, Food, Mount Vesuvius, Human, Computer, LLM, Thiel Fellowship, Catholic Church, Herculaneum papyri, Architecture, Investment, Decentralized finance, Fruit, Thiel Foundation, Roman Empire, Cognition, Silicon

The Thiel Foundation has unveiled the 2024 class of Thiel Fellows, assembling a group of 20 brilliant young minds who are set to disrupt various industries.

Key Points: 
  • The Thiel Foundation has unveiled the 2024 class of Thiel Fellows, assembling a group of 20 brilliant young minds who are set to disrupt various industries.
  • Established in 2011, the Thiel Fellowship provides each recipient with $100,000 and access to a powerful network of tech founders, investors, scientists, and former fellows.
  • They reject the well-worn paths of red tape, digital distractions, and self-censorship,” said Alex Handy, director of the Thiel Fellowship.
  • “By refusing to sit idle while others succumb to conformity’s paralysis, they’re positioned to finally deliver on the future.”
    The new class joins 270 previous fellows.

Meet Lydia: Alai Studios and Shaping Wealth Deploy Next-Gen AI to Usher in The Future of Financial Advice

Retrieved on: 
Tuesday, March 19, 2024
Technology, Personal Finance, Finance, Fintech, Other Technology, Professional Services, Software, Asset Management, Artificial Intelligence, Automation, UX, Learning, Intelligence, Empathy, Emotional intelligence, AI, Neuroscience, Psychology, Studio, CFA, Happiness, Cognition, Emotion, Management

Alai Studios and Shaping Wealth announced today the launch of Lydia , the future of financial advice.

Key Points: 
  • Alai Studios and Shaping Wealth announced today the launch of Lydia , the future of financial advice.
  • Alai and Shaping Wealth are jointly committed to a "human first" approach to financial guidance, ensuring that AI’s implementation into wealth management amplifies human brilliance.
  • "At Shaping Wealth, we're focused on transforming financial guidance's essence through behavioral science," said Shaping Wealth's Founder, Brian Portnoy, Ph.D., CFA.
  • Alai and Shaping Wealth are leading this shift by embracing the role that technology can play in humanity’s broader search for contentment and meaning.

Sixth Generation Wireless, by 6G Tech Development and 6G Market Commercialization, Use Cases and Industry Verticals 2024-2030 - ResearchAndMarkets.com

Retrieved on: 
Monday, March 18, 2024
Technology, Mobile, Wireless, Deployment, Communication, Intelligence, Research, Lead, Electronics, Radio access network, Infrastructure, RF, Terahertz, Investment, Radio, Cognition, Miniaturization, RIS, Radio frequency, Machine learning, MIMO, RAN, Renewable energy

The "Sixth Generation Wireless by 6G Tech Development (Investment, R&D and Testing) and 6G Market Commercialization (Infrastructure, Deployment, Apps and Services), Use Cases and Industry Verticals 2024 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Sixth Generation Wireless by 6G Tech Development (Investment, R&D and Testing) and 6G Market Commercialization (Infrastructure, Deployment, Apps and Services), Use Cases and Industry Verticals 2024 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The report evaluates investments, research and development (R&D), and the prototyping and testing stages of 6G technologies, preparing the industry for the forthcoming evolutionary leap in wireless communication.
  • The report delves into the commercialization of the 6G market, spotlighting opportunities across infrastructure development, equipment deployment, and the innovation horizon in applications and services.
  • Industry insiders and market stakeholders are furnished with insights on an array of 6G market use cases by industry vertical, equipping them with actionable intelligence to make informed decisions in line with emerging trends.

Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

Retrieved on: 
Wednesday, March 13, 2024
Alternative Medicine, Mental Health, Health, FDA, Clinical Trials, Pharmaceutical, Biotechnology, JAMA, Depression, Disability, Conference, BTD, Breakthrough therapy, Massachusetts General Hospital, Inc., Psychiatry, Clinical, Grammatical mood, Appetite, MDD, Data analysis, Patient, Knowledge, Disease, Causality, Sleep, Anhedonia, DNB, DSM-IV codes, MBBS, Suicidal ideation, Behavior, Cognition, Event, Hospital, Drug development, Safety, Injury, Multimedia, Plasma protein binding, Sadness, Lancet, BMJ, Pharmaceutical industry

If approved by the FDA, CYB003 would be the first known adjunctive psychedelic-based therapeutic for the treatment of MDD.

Key Points: 
  • If approved by the FDA, CYB003 would be the first known adjunctive psychedelic-based therapeutic for the treatment of MDD.
  • The designation of CYB003 as a breakthrough therapy acknowledges the significant unmet medical need for more effective treatments of MDD and supports CYB003’s potential for significant improvements over existing therapies.
  • With the robust durability data from our Phase 2 study in hand, we are ready to move forward expeditiously.
  • (2022) Response to acute monotherapy for major depressive disorder in randomized, placebo-controlled trials submitted to the US Food and Drug Administration: individual participant data analysis.

Deepcell Delivers Final Beta Testing Instruments Ahead of Full REM-I Platform Launch

Retrieved on: 
Wednesday, March 13, 2024
Software, Research, Pharmaceutical, Oncology, Technology, Medical Devices, Infectious Diseases, Genetics, Artificial Intelligence, Science, Biotechnology, Stem Cells, Health, Gene, Flow cytometry, Gene expression, Intelligence, Cell biology, Allergy, Newcastle University, Developmental biology, Doctor of Philosophy, Genotype, EMBL, Axon, Eosinophil, Cognition, Neutrophil, Liver cancer, Machine learning, European, Bone marrow, Microscope

Deepcell, a pioneer in artificial intelligence (AI)-powered single cell analysis to fuel deep biological discoveries, today announced the launch of its Beta Program for the REM-I platform .

Key Points: 
  • Deepcell, a pioneer in artificial intelligence (AI)-powered single cell analysis to fuel deep biological discoveries, today announced the launch of its Beta Program for the REM-I platform .
  • The participants will use the technology to study plasma disorders, blood cancers, immunological functions, genetic perturbations, and other cellular processes.
  • The REM-I platform is a high-dimensional cell morphology analysis and sorting platform which comprises the REM-I benchtop instrument, an AI Foundation Model, and Axon data suite.
  • “Deepcell's method of integrating artificial intelligence and single cell analysis remains unique in the industry,” said Maddison Masaeli, Ph.D., co-founder and chief executive officer at Deepcell.

Prilenia Plans to Submit Marketing Authorization Application (MAA) in the EU for Pridopidine in Huntington’s Disease

Retrieved on: 
Tuesday, March 12, 2024
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, MAA, DSM-IV codes, ALS, Patient, Committee, EMA, ADM, VMAT2, European, Therapy, Cognition, FDA, CHMP, Neurodegenerative disease, Food, Pharmaceutical industry

“Pridopidine demonstrates consistent treatment benefits across independent measures that are important to patients and families.

Key Points: 
  • “Pridopidine demonstrates consistent treatment benefits across independent measures that are important to patients and families.
  • The benefits are clearly evident in those with HD who are not taking anti-dopaminergic medications (ADM),” said Dr. Michael R. Hayden, CEO of Prilenia.
  • “We appreciate the constructive discussions with European regulators regarding our data for pridopidine.
  • The Company will also consider global regulatory submissions for additional countries and regions following the regulatory review process in Europe.

air up®'s April Fools Campaign Sheds Light On Americans' Peeing Habits

Retrieved on: 
Tuesday, April 2, 2024
Health, Perspiration, Mental health, Fool, Joint, Drinking, Urine, Dehydration, Cognition, Water, Habit, Clutch (eggs), LOS, Sawmill

With this campaign, air up® aimed to spark a national conversation about the importance of proper hydration, particularly in light of the fact that 61% of Americans express current or past concerns about the color of their urine.

Key Points: 
  • With this campaign, air up® aimed to spark a national conversation about the importance of proper hydration, particularly in light of the fact that 61% of Americans express current or past concerns about the color of their urine.
  • Lena Jüngst, Co-Founder of air up®, explains, "Rest assured, we're not launching a pee-flavored pod.
  • The attention-grabbing tactic is part of a broader educational campaign to highlight the release of air up's® recent survey shedding light on Americans' peeing habits.
  • While the findings underscore positive awareness of urine's significance as a marker for hydration and overall health, significant gaps remain.

Bio-K Plus expands its portfolio of functional probiotics with its new Extra Stress Support with Sensoril® probiotic drinkable to meet consumers' demand for science-powered products with multiple benefits

Retrieved on: 
Thursday, March 28, 2024
Research, Health, Kerry Group, Taste, Withania somnifera, Withania, Probiotic, Food, Seed, Marketing, Cognition, Whole Foods Market, Multimedia, Dietary supplement

MONTREAL, March 28, 2024 /PRNewswire/ - Bio-K Plus, a Kerry Company, pioneer in the probiotic sector, is pleased to announce the launch of its new functional drinkable probiotic, the Extra Stress Support with Sensoril®.

Key Points: 
  • MONTREAL, March 28, 2024 /PRNewswire/ - Bio-K Plus, a Kerry Company, pioneer in the probiotic sector, is pleased to announce the launch of its new functional drinkable probiotic, the Extra Stress Support with Sensoril®.
  • Sensoril® is a plant-based premium ashwagandha extract (withania somnifera) renowned for managing everyday stress and promoting emotional well-being.
  • All of this is delivered in the form of a delicious lemon and ginger-flavored drinkable probiotic, that tastes like a fresh smoothie.
  • Source: Market Future Research: Functional Beverages Market Research Report – Market Forecast Till 2023, February 20211
    View original content to download multimedia: https://www.prnewswire.com/news-releases/bio-k-plus-expands-its-portfoli...

World's first field-installed, clinically approved parallel transmit 7T MRI scanner resides at Auburn University

Retrieved on: 
Tuesday, March 26, 2024
College, Epilepsy, Physics, Friends, Brain, MRI, Cell, Terra, Multiple sclerosis, Magnetic resonance imaging, Homeostasis, Biomedical Research, Post-traumatic stress disorder, Intelligence, Patient, Physiology, Physician, Education, DSM-IV codes, Tay–Sachs disease, Research, Gold, History, Economic development, Biomarker, Auburn University, Light, Sodium, Computer engineering, Electricity, Parkinson's disease, Cognition, Veterinary medicine, Liberal arts education, Multimedia, Disorder, Emotion, Engineering, Food, Medical imaging

Additionally, with dedicated radiofrequency sodium imaging coils and parallel transmit technology, the scanner offers expanded imaging capabilities.

Key Points: 
  • Additionally, with dedicated radiofrequency sodium imaging coils and parallel transmit technology, the scanner offers expanded imaging capabilities.
  • These areas represent an intersection between the needs of the MRI research community, particularly in 7T imaging, and existing expertise and strengths of Auburn University.
  • A stark difference between the old and new 7T scanners involve parallel transmit technology and sodium imaging capability.
  • "If it wasn't for them, we wouldn't have the 7T, and we are indebted to them for their dedication and commitment to Auburn.